About Chromadex Corp
Ticker
info
CDXC
Trading on
info
NASDAQ
ISIN
info
US1710774076
Industry
info
Packaged Foods
Sector
info
Consumer Defensive
CEO
info
Robert N. Fried
Headquarters
info
10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
Employees
info
106
Website
info
chromadex.com
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Metrics
BasicAdvanced
Market cap
info
$653M
P/E ratio
info
427.5
EPS
info
$0.02
Dividend Yield
info
0.00%
Beta
info
2.21
Forward P/E ratio
info
43.29
EBIDTA
info
$1.3M
Ex dividend date
info
-
Price & volume
Market cap
info
$653M
Average daily volume
info
1.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
427.5
Forward P/E
info
43.29
PEG ratio
info
0
Trailing P/E
info
427.5
Price to sales
info
7.12
Price to book
info
12.49
Earnings
EPS
info
$0.02
EPS estimate (current quarter)
info
$0.02
EPS estimate (next quarter)
info
$0.02
EBITDA
info
$1.3M
Revenues (TTM)
info
$91.7M
Revenues per share (TTM)
info
$1.22
Technicals
Beta
info
2.21
52-week High
info
$9.18
52-week Low
info
$1.61
50-day moving average
info
$5.61
200-day moving average
info
$4.37
Short ratio
info
6.89
Short %
info
4.44%
Management effectiveness
ROE (TTM)
info
4.82%
ROA (TTM)
info
0.51%
Profit margin
info
1.62%
Gross profit margin
info
$56.3M
Operating margin
info
6.26%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
31.20%
Share stats
Outstanding Shares
info
76.4M
Float
info
49.5M
Insiders %
info
35.62%
Institutions %
info
30.27%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 5 analysts.

Average price target

info
$8.22
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.01
-$0.02
50.00%
Q1 • 24Beat
-$0.00
-$0.02
99.00%
Q2 • 24Beat
$0.02
$0.01
100.00%
Q3 • 24Beat
$0.03
$0.02
72.22%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$34.9M
$1.9M
5.38%
Q3 • 24
$18.2M
$7.2M
39.45%
Q4 • 24
47.89%
282.27%
633.57%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$56.5M
$22.2M
39.19%
Q3 • 24
$66.2M
$20.1M
30.36%
Q4 • 24
17.11%
9.28%
22.53%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-0.3M
$-0M
$0.6M
$-0.3M
Q2 • 24
$3.5M
$-0M
$1M
$3.5M
Q3 • 24
1,423.86%
75.00%
74.33%
1,351.45%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.43

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Chromadex Corp share?
Collapse

Chromadex Corp shares are currently traded for undefined per share.

How many shares does Chromadex Corp have?
Collapse

Chromadex Corp currently has 76.4M shares.

Does Chromadex Corp pay dividends?
Collapse

No, Chromadex Corp doesn't pay dividends.

What is Chromadex Corp 52 week high?
Collapse

Chromadex Corp 52 week high is $9.18.

What is Chromadex Corp 52 week low?
Collapse

Chromadex Corp 52 week low is $1.61.

What is the 200-day moving average of Chromadex Corp?
Collapse

Chromadex Corp 200-day moving average is $4.37.

Who is Chromadex Corp CEO?
Collapse

The CEO of Chromadex Corp is Robert N. Fried.

How many employees Chromadex Corp has?
Collapse

Chromadex Corp has 106 employees.

What is the market cap of Chromadex Corp?
Collapse

The market cap of Chromadex Corp is $653M.

What is the P/E of Chromadex Corp?
Collapse

The current P/E of Chromadex Corp is 427.5.

What is the EPS of Chromadex Corp?
Collapse

The EPS of Chromadex Corp is $0.02.

What is the PEG Ratio of Chromadex Corp?
Collapse

The PEG Ratio of Chromadex Corp is 0.

What do analysts say about Chromadex Corp?
Collapse

According to the analysts Chromadex Corp is considered a buy.